These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 19267392)
1. Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women. Honjo H; Kawauchi A; Ukimura O; Nakao M; Kitakoji H; Miki T Neurourol Urodyn; 2009; 28(8):982-5. PubMed ID: 19267392 [TBL] [Abstract][Full Text] [Related]
2. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103 [TBL] [Abstract][Full Text] [Related]
3. Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298 [TBL] [Abstract][Full Text] [Related]
4. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704 [TBL] [Abstract][Full Text] [Related]
5. Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome. Chung SD; Liao CH; Chen YC; Kuo HC Neurourol Urodyn; 2011 Sep; 30(7):1300-4. PubMed ID: 21560153 [TBL] [Abstract][Full Text] [Related]
6. Understanding the elements of overactive bladder: questions raised by the EPIC study. Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K; BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602 [TBL] [Abstract][Full Text] [Related]
7. Overactive bladder is not only overactive but also hypersensitive. Lee SR; Kim HJ; Kim A; Kim JH Urology; 2010 May; 75(5):1053-9. PubMed ID: 20092879 [TBL] [Abstract][Full Text] [Related]
8. Impact of convenience void in a bladder diary with urinary perception grade to assess overactive bladder symptoms: a community-based study. Honjo H; Kawauchi A; Nakao M; Ukimura O; Kitakoji H; Miki T Neurourol Urodyn; 2010 Sep; 29(7):1286-9. PubMed ID: 20878998 [TBL] [Abstract][Full Text] [Related]
9. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT). Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Wagg A; Wyndaele JJ; Sieber P Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617 [TBL] [Abstract][Full Text] [Related]
11. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Kuo HC; Liu HT; Chancellor MB Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641 [TBL] [Abstract][Full Text] [Related]
12. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder. Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957 [TBL] [Abstract][Full Text] [Related]
14. Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. Hung MJ; Ho ES; Shen PS; Sun MJ; Lin AT; Chen GD; J Urol; 2006 Aug; 176(2):636-40. PubMed ID: 16813910 [TBL] [Abstract][Full Text] [Related]
15. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC; BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767 [TBL] [Abstract][Full Text] [Related]
16. Comparison of sensation-related voiding patterns between continent and incontinent women: a study with a 3-day sensation-related bladder diary (SR-BD). Naoemova I; De Wachter S; Wyndaele JJ Neurourol Urodyn; 2008; 27(6):511-4. PubMed ID: 18092332 [TBL] [Abstract][Full Text] [Related]
17. How do urinary diaries of women with an overactive bladder differ from those of asymptomatic controls? Fitzgerald MP; Ayuste D; Brubaker L BJU Int; 2005 Aug; 96(3):365-7. PubMed ID: 16042731 [TBL] [Abstract][Full Text] [Related]
18. Aging and overactive bladder may be associated with loss of urethral sensation in women. Kenton K; Lowenstein L; Simmons J; Brubaker L Neurourol Urodyn; 2007; 26(7):981-4. PubMed ID: 17626276 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833 [TBL] [Abstract][Full Text] [Related]
20. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Wennberg AL; Molander U; Fall M; Edlund C; Peeker R; Milsom I Eur Urol; 2009 Apr; 55(4):783-91. PubMed ID: 19157689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]